Zydus receives US FDA marketing nod for morphine sulfate ER tablets
US Food and Drug Administration (FDA) has granted marketing authorisation for morphine sulfate ER tablets. A subsidiary of Zydus Pharmaceuticals (USA) Inc., Nesher has considerable expertise in niche therapies with development or products barriers, such as controlled release medications and DEA-controlled substances. Morphine sulfate ER tablets used in the treatment of chronic pain or cancer related pain. The product will be manufactured at Nesher Pharmaceuticals (USA) LLC, located at St. Louis, USA.